Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Ziv-aflibercept Pregnancy and Breastfeeding Warnings

Ziv-aflibercept is also known as: Zaltrap

Medically reviewed by Last updated on Oct 29, 2018.

Ziv-aflibercept Pregnancy Warnings

Ziv-aflibercept has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of embryo-fetal toxicity and teratogenicity. There are no controlled data in human pregnancy. The manufacturer recommends that females and males of reproductive potential should use highly effective contraception during and up to a minimum of 3 months after the last dose of treatment. If ziv-aflibercept is used during pregnancy, or if the patient becomes pregnant during treatment, the patient should be apprised of the potential hazard to the developing fetus. The manufacturer recommends that ziv-aflibercept only be used during pregnancy when the potential benefits outweigh the potential risks to the developing fetus.

See references

Ziv-aflibercept Breastfeeding Warnings

There are no data on the excretion of ziv-aflibercept into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Zaltrap (ziv-aflibercept)." sanofi-aventis , Bridgewater, NJ.

References for breastfeeding information

  1. "Product Information. Zaltrap (ziv-aflibercept)." sanofi-aventis , Bridgewater, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.